Skip to content

Study · Randomized controlled trial · n = 54 · 2009

4 results

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP

Gastroenterology29 Jul 2009Cited by 176 (Europe PMC)

PMID19646443 (opens in a new tab)DOI10.1053/j.gastro.2009.07.052 (opens in a new tab)PepBankPUB-19646443
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with polycystic liver, lanreotide reduced liver volume whereas placebo increased it.

    In plain wordsIn patients with polycystic liver, liver volume decreased with lanreotide and increased with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseLiver volume versus placebo
    Study

    n = 54

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    Liver volume change
    −2.9%
    lanreotide
    Liver volume change
    1.6%
    placebo
    Baseline liver volume
    4606 mL
    lanreotide
    Final liver volume
    4471 mL
    lanreotide
    Baseline liver volume 95% CI
    547 to 8665 mL
    lanreotide
    Final liver volume 95% CI
    542 to 8401 mL
    lanreotide
    Baseline liver volume
    4689 mL
    placebo
    Final liver volume
    4895 mL
    placebo

    3 more measurements in the study.

    Source sentences

    Summary
    The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
    2 context sentences
    Summary · context
    In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
    Summary · context
    Patients with polycystic liver (n = 54) were randomly assigned to groups given lanreotide (120 mg) or placebo, administered every 28 days for 24 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with polycystic liver, mean liver volume decreased during lanreotide treatment.

    In plain wordsIn patients with polycystic liver, liver volume decreased during lanreotide treatment.

    Peptide
    Lanreotide
    Outcome
    DecreaseMean liver volume
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    Mean liver volume change
    −2.9%
    reported result
    Baseline liver volume
    4606 mL
    reported result
    Final liver volume
    4471 mL
    reported result
    Baseline confidence interval
    547 to 8665 mL
    95% CI
    Final confidence interval
    542 to 8401 mL
    95% CI

    Source sentences

    Summary
    The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
    1 context sentence
    Summary · context
    Patients with polycystic liver (n = 54) were randomly assigned to groups given lanreotide (120 mg) or placebo, administered every 28 days for 24 weeks.
  3. 03HumanObservational studyEfficacy outcome

    In a post hoc analysis stratified by disease, patients with ADPKD given lanreotide had a statistically significant difference in liver volume (P < .01); changes were similar in ADPKD and PCLD.

    In plain wordsIn patients with ADPKD given lanreotide, a post hoc analysis found a statistically significant difference in liver volume.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedLiver volume in ADPKD
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    P
    < 0.01
    ADPKD; post hoc stratification, reported as P < .01 for both diseases

    Source sentences

    Summary
    Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
    2 context sentences
    Summary · context
    The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
    Summary · context
    Patients with polycystic liver (n = 54) were randomly assigned to groups given lanreotide (120 mg) or placebo, administered every 28 days for 24 weeks.
  4. 04HumanObservational studyEfficacy outcome

    In a post hoc analysis stratified by disease, patients with PCLD given lanreotide had a statistically significant difference in liver volume (P < .01); changes were similar in ADPKD and PCLD.

    In plain wordsIn patients with PCLD given lanreotide, a post hoc analysis found a statistically significant difference in liver volume.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedLiver volume in PCLD
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    120 mg every 28 days · 24 weeksAs given in this study (human).

    Measurements

    P
    < 0.01
    PCLD; post hoc stratification, reported as P < .01 for both diseases

    Source sentences

    Summary
    Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
    2 context sentences
    Summary · context
    The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
    Summary · context
    Patients with polycystic liver (n = 54) were randomly assigned to groups given lanreotide (120 mg) or placebo, administered every 28 days for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01354405

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

Radboud University Medical Centern = 43May 2011 to Jun 2014

Polycystic Liver Disease

Trial pageClinicalTrials.govUpdated 9 Jul 2014
CompletedPhase 2/3NCT01315795

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

Universitaire Ziekenhuizen KU Leuvenn = 59Mar 2011 to Jul 2014

Polycystic Liver Disease

Trial pageClinicalTrials.govUpdated 8 Jul 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.